Cellectis Outlines 2026 Strategy, Highlighting Pivotal Phase 2 Lasme-cel Data and Eti-cel Phase 1 Results

summarizeSummary

Cellectis announced its 2026 strategic priorities, including key clinical data readouts for its lead CAR-T programs, lasme-cel and eti-cel, and confirmed its cash runway into the second half of 2027.

check_boxKey Events

• Pivotal Phase 2 Lasme-cel Data Expected

  Cellectis anticipates completing the first interim analysis of its pivotal Phase 2 BALLI-01 clinical trial for lasme-cel in r/r B-ALL in Q4 2026, building on encouraging Phase 1 efficacy and safety data.

• Full Phase 1 Eti-cel Data and New Cohort

  The company expects to report the full Phase 1 dataset for eti-cel in r/r NHL in Q4 2026, following the initiation of patient enrollment in a low-dose interleukin-2 support cohort in Q1 2026 to enhance response rates.

• Extended Cash Runway

  Cellectis projects its cash, cash equivalents, and fixed-term deposits will be sufficient to fund operations into the second half of 2027.

• Strategic Partnership Progress

  Activities are progressing under the Joint Research and Collaboration Agreement with AstraZeneca, and updates were provided on partner-led trials for cema-cel (Servier/Allogene) and IOV-4001 (Iovance).

auto_awesomeAnalysis

Cellectis' 2026 strategic outline provides investors with a clear roadmap of critical clinical milestones for its lead allogeneic CAR-T candidates. The anticipated interim data from the pivotal Phase 2 BALLI-01 trial for lasme-cel in Q4 2026 is a significant catalyst, as is the full Phase 1 dataset for eti-cel. Positive outcomes from these trials are crucial for the company's valuation and future development. The extended cash runway into H2 2027 provides financial stability to execute on these plans.